Denali Therapeutics (DNLI) Cash from Financing Activities (2017 - 2026)

Denali Therapeutics (DNLI) has reported Cash from Financing Activities for 10 consecutive years, with $219.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 5922.54% year-over-year to $219.0 million; the TTM figure through Mar 2026 stood at $412.0 million (up 2187.98% YoY), while the FY2025 annual figure was $189.2 million, down 60.93% from the prior year.
• Cash from Financing Activities advanced to $219.0 million in Q1 2026 per DNLI's latest filing, from $192.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $500.3 million in Q1 2024 and bottomed at -$18.6 million in Q3 2024.
• Historically, Cash from Financing Activities has averaged $71.8 million across 5 years, with a median of $4.4 million in 2022.
• On a YoY basis, Cash from Financing Activities climbed as much as 31089.21% in 2024 and fell as far as 844.74% in 2024.
• Denali Therapeutics' Cash from Financing Activities stood at $299.7 million in 2022, then plunged by 98.43% to $4.7 million in 2023, then slumped by 188.59% to -$4.2 million in 2024, then surged by 4709.72% to $192.1 million in 2025, then rose by 14.01% to $219.0 million in 2026.
• Business Quant data shows DNLI's Cash from Financing Activities at $219.0 million in Q1 2026, $192.1 million in Q4 2025, and -$778000.0 in Q3 2025.